The combination of capivasertib and fulvestrant was further explored in a randomized, placebo-controlled phase II trial (FAKTION), which enrolled postmenopausal women with HR+/HER2-advanced BC relapsing after or progressing on an aromatase inhibitor (AI). This evidence concerns the gene ERBB2 and breast cancer.